Nidan Laboratories and Healthcare Limited — Results, 19-12-2024: Reply to Clarification- Financial results

Total income for the half-year ended September 30, 2024, is reported at ₹1,156.36 crore, reflecting a decline of approximately 13.3% compared to ₹1,334.74 crore for the same period last year. This drop in revenue may be attributed to adverse market conditions or reduced demand for healthcare services.

Net profit for the period stands at ₹110.13 crore, markedly lower than ₹192.24 crore in the previous year, indicating challenges in maintaining profitability. The earnings per share (EPS) is reported at ₹0.79, down from ₹1.38 year-over-year, driven by increased operational costs and potential reductions in service uptake.

Operational costs saw a total of ₹1,014.99 crore, down approximately 5.5% from ₹1,074.56 crore in the previous period, partly due to tightened cost controls. However, ongoing expenses, including finance costs and employee benefits, remain high, impacting overall margin stability.

The balance sheet shows total assets of ₹8,345.15 crore, indicating a solid asset base with a slight increase from ₹8,255.08 crore as of March 31, 2024. Cash and cash equivalents at the end of this period decreased marginally to ₹279.54 crore from ₹284.99 crore, reflecting cautious liquidity management.

Strategically, Nidan Laboratories appears focused on enhancing operational efficiency and managing costs to stabilize financial performance amidst market challenges. Market sentiment may remain cautious due to the declining revenue trend and profitability pressures.

Considering the current financial performance and market outlook, the suggestion is to hold the stock, as there may be potential for recovery if operational efficiencies improve and market conditions stabilize.